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ABSTRACT Burkholderia thailandensis produces a family of polyketide-peptide molecules called bactobolins, some of which are
potent antibiotics. We found that growth of B. thailandensis at 30°C versus that at 37°C resulted in increased production of bac-
tobolins.Wepuriﬁedthethreemostabundantbactobolinsanddeterminedtheiractivitiesagainstabatteryofbacteriaand
mouseﬁbroblasts.Twoofthethreecompoundsshowedstrongactivitiesagainstbothbacteriaandﬁbroblasts.Thethirdanalog
wasmuchlesspotentinbothassays.Theseresultssuggestedthatthetargetofbactobolinsmightbeconservedacrossbacteria
andmammaliancells.Tolearnaboutthemechanismofbactobolinactivity,weisolatedfourspontaneousbactobolin-resistant
Bacillus subtilis mutants. We used genomic sequencing technology to show that each of the four resistant variants had muta-
tionsinrplB,whichcodesforthe50Sribosome-associatedL2protein.Ectopicexpressionofamutant rplBgeneinwild-type
B. subtilis conferred bactobolin resistance. Finally, the L2 mutations did not confer resistance to other antibiotics known to in-
terferewithribosomefunction.OurdataindicatethatbactobolinstargettheL2proteinoranearbysiteandthatthisisnotthe
targetofotherantibiotics.WepresumethatthemammaliantargetofbactobolinsinvolvestheeukaryotichomologofL2(L8e).
IMPORTANCE Currentlyavailableantibioticstargetsurprisinglyfewcellularfunctions,andthereisaneedtoidentifynovelanti-
biotic targets. We have been interested in the Burkholderia thailandensis bactobolins, and we sought to learn about the target of
bactobolin activity by mapping spontaneous resistance mutations in the bactobolin-sensitive Bacillus subtilis. Our results indi-
catethatthebactobolintargetisthe50Sribosome-associatedL2proteinoraregionoftheribosomeaffectedbyL2.Bactobolin-
resistantmutantsarenotresistanttootherknownribosomeinhibitors.Ourevidenceindicatesthatbactobolinsinteractwitha
novelantibiotictarget.
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T
he saprophyte Burkholderia thailandensis has a large genome
with at least a dozen gene clusters with predicted polyketide
synthase (PKS) and/or nonribosomal peptide synthetase (NRPS)
genes (for a detailed list, see reference 1). One of the PKS/NRPS
hybrid clusters is involved in the production of eight identiﬁed
bactobolin compounds (Fig. 1). Some of the bactobolins are po-
tent antibiotics (2, 3). These water-soluble compounds consist of
aC 6-polyketide fused to a chlorinated hydroxy-valine residue.
Bactobolins A to C were ﬁrst characterized in the late 1970s as
potent, broad-spectrum antibiotics produced by a poorly de-
scribed pseudomonad. Preparations were toxic to mammalian
cells, and perhaps because of this, the interest in bactobolins
waned (3–5). We recently discovered ﬁve new bactobolins (D to
H) and a cluster of genes involved in bactobolin biosynthesis (the
genes are BTH_II1222 to BTH_II1242 from genomic coordinates
1445675to1482269;see http://www.burkholderia.com),whichis
reasonablywellconservedintherelatedspeciesBurkholderiapseu-
domallei (2, 3, 6). We also showed that bactobolin production is
dependent on one of the three acyl-homoserine lactone (acyl-
HSL) quorum-sensing circuits in B. thailandensis, the BtaI2–
BtaR2–N-3-hydroxydecanoyl HSL (3OHC10-HSL) circuit (6).
Thebroad-spectrumactivitiesofbactobolinssuggesttheymay
have a conserved target (2, 3), and results from one study indi-
catedthatbactobolinsinhibitproteinsynthesis(7),asistruefora
numberofotherantibiotics.Althoughthe50Sand30Ssubunitsof
the bacterial 70S ribosome contain 20 and 34 proteins, respec-
tively, the subunits consist predominantly of RNA, and the RNAs
serve as the target of most ribosome-inhibiting antibiotics. Anti-
biotic activity most often occurs at one of three key sites: the
codon-anticodon recognition site (A site) on the 30S subunit, the
peptidyl-transferase center (PTC) on the 50S subunit, or the pep-
tide exit tunnel on the 50S subunit. Aminoglycoside antibiotics
interfere with codon recognition and speciﬁcity at the A site. An-
tibiotics such as chloramphenicol, clindamycin, and linezolid in-
terfere with peptide bond formation at the PTC. Macrolides such
as erythromycin block elongation of the growing peptide chain at
thepeptideexittunnel(forrecentreviews,seereferences8and9).
Several antibiotics can bind the same or an overlapping site, and
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many different antibiotics (10, 11).
Tobetterunderstandthemechanismofactionofthebactobo-
lin antibiotics, we developed conditions to improve bactobolin
production by B. thailandensis. We puriﬁed the most abundant
bactobolins and showed they have a broad spectrum of activity
that includes bacteria and mouse cells. We then mapped Bacil-
lussubtilisbactobolinresistancemutationstoaspeciﬁcregionofa
50S ribosomal subunit protein called L2. Our evidence supports
theviewthattheL2proteinisabactobolintargetordirectlymod-
iﬁes the target on the ribosome.
RESULTS
Bactobolinproductionistemperatureregulated.Wefoundthat,
due to bactobolins, ﬂuid from B. thailandensis cultures grown at
30°C inhibited growth of Escherichia coli in a ﬁlter disk assay,
whereasﬂuidfrom37°Cculturesdidnot(Fig.2,top).Weposited
that the higher activity at 30°C could be because bactobolins are
heatsensitiveorbecauseproductionishigherat30°C.Todiscrim-
inate between these two possibilities, we grew B. thailandensis at
30°C, removed cells by ﬁltration, incubated the culture ﬂuid at
temperaturesrangingfrom30°Cto80°Cfor2h,andthenassessed
antimicrobial activity by using the E. coli ﬁlter disk assay. We
foundthatantimicrobialactivityinﬁlteredcultureﬂuidwasstable
up to 60°C (Fig. 2, bottom). Thus, we concluded that production
of bactobolins is higher at 30°C than it is at 37°C.
We then used a B. thailandensis strain with a chromosomally
encodedlacZgenefusedtothebactobolinsynthesisgenebtaK(6)
to assess whether enhanced production of bactobolins at 30°C
might result from enhanced transcription of a bactobolin synthe-
sis gene(s). The -galactosidase reporter activity peaked in early
stationary-phase cells grown at either 30°C or 37°C, and it was 2-
to 3-fold higher at 30°C than at 37°C (Fig. 3). Consistent with a
previous study, btaK expression was greatly reduced in a btaR2
quorum-sensingreceptormutant(6).Weconcludethatbactobo-
lin production is greater at 30°C than at 37°C as a result of en-
hancedtranscriptionofatleastoneofthebactobolinbiosynthesis
genes at 30°C.
Bactobolins A and C are potent and have broad-spectrum
activity. We determined the MICs of puriﬁed bactobolins A, B,
and C for a diverse set of pathogenic and environmental bacteria
(Table1).WefoundthatbothbactobolinAandbactobolinCwere
particularlyactiveagainstmanyGram-positiveandProteobacteria
species, including vancomycin-intermediate resistant Staphylo-
coccus aureus isolates (VISA) (bactobolin A MIC, 3 g/ml). Bac-
tobolin A was generally more potent than bactobolin C. We also
testedbactobolinBandfoundithadrelativelylittleornomeasur-
able activity against the bacteria we tested (Table 1). Several spe-
cies, including two close relatives of B. thailandensis, B. pseu-
FIG1 Bactobolinstructures.BactobolinsAandCvaryfromBandDattheR2
position.
FIG 2 Susceptibility of E. coli to antibiotics in B. thailandensis culture ﬂuid
(top). Paper ﬁlter disks were saturated with ﬁltered ﬂuid from B. thailandensis
cultures grown at 30°C or 37°C, and the ﬁlters were placed on a growing lawn
ofE.coliDH10B(bottom).FluidfromB.thailandensisculturesgrownat30°C
wastreatedfor2hattherangeoftemperaturesindicatedpriortobeingapplied
to the ﬁlter disks.
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bactobolins. There may be a conserved resistance mechanism in
B. thailandensis, B. pseudomallei, and B. mallei. Of note, B. mallei
haslost120kbofDNAcontaining,amongmanyotheropenread-
ing frames, the bactobolin biosynthetic gene locus. Thus, the re-
sistance of these three species may not be encoded within the
bactobolin gene locus or adjacent DNA.
Previous studies have shown that bactobolin preparations are
toxic to mammalian cells (7). Because these preparations may
haveincludedmorethanoneoftheeightbactobolinsproducedby
B. thailandensis, we assessed the cytotoxicities of puriﬁed bacto-
bolinsA,B,andC.WealsoassessedthetoxicityofbactobolinD,a
compound we only recently discovered (3). The concentration of
bactobolin A required to cause a 50% decrease in viability, the
ID50, of cultured mouse NIH 3T3 ﬁbroblast cells was 0.6 g/ml,
comparable to ﬁndings in a previous study (7). The ID50 of bac-
tobolin C was similar (0.7 g/ml). Bactobolins B and D were less
cytotoxic (ID50s, 1.5 and 1.7 g/ml, respectively). Thus, for bac-
tobolins A to C, cytotoxicity correlates with antibacterial activity
(Table 1). The more active bactobolins A and C do not have an
alanineattheR2position(Fig.1).WesuspectthatalanineattheR2
position may reduce the bioactivity of bactobolins. The correla-
tion of activities with mouse cells and bacterial cells indicates that
thetargetofbactobolinactivityisconservedinbiologicalsystems.
Isolationofspontaneousbactobolin-resistantB.subtilismu-
tants. Our approach toward identiﬁcation of the cellular target of
bactobolinswastoisolatespontaneousbactobolin-resistantBacil-
lus subtilis mutants and then deﬁne the mutations leading to re-
sistance. We chose B. subtilis 3610 for this analysis because it is
FIG 3 Temperature-dependent expression of btaK and acyl-HSLs. Closed
symbolsandbarsrepresentculturesgrownat30°C,andopensymbolsandbars
represent cultures grown at 37°C. Expression of a chromosomal btaK-lacZ
reporterinthewildtype(circles)orthebtaR2mutant(squares)isshown.The
data are the means for three biological replicates, and the error is the range.
TABLE 1 Antimicrobial activities of bactobolins
Species and strain
MIC (g per ml)a
Reference or source AB C
Bacillus cereus ATCC 14579 13 ND 38 (13) ATCCb
Bacillus subtilis 3610c 0.39 12.5 1.56 ATCC
Burkholderia cenocepacia K56-2 50 ND 100 56
Burkholderia kururiensis M130 13 ND 50 Brazild
Burkholderia mallei ATCC 23344 100 ND ND 57
Burkholderia pseudomallei 1026b 100 ND ND 58
Burkholderia pseudomallei 1258b 100 ND ND Thailandd
Burkholderia pseudomallei E0274 100 ND ND Thailandd
Burkholderia vietnamiensis G4 0.78 ND 6 59
Candida krusei ATCC 14243 100 ND 100 60
Chromobacterium violaceum CV017 2 (0.8) ND 13 61
Escherichia coli 100110 38 (13) ND ND UWd
Escherichia coli 090428 50 ND ND UWd,e
Flavobacterium johnsoniae CI04 6 ND 25 62
Haemophilus inﬂuenzae ATCC 10211 100 ND 100 ATCC
Klebsiella pneumoniae 19 (6) 100 100 63
Mycobacterium marinum BAA535 6 100 50 64
Proteus mirabilis HI4320 100 100 100 65
Pseudomonas aeruginosa PA14 50 100 100 66
Pseudomonas aeruginosa ATCC 25873 100 100 100 ATCC
Pseudomonas ﬂuorescens 2-79 0.19 9.3(3) 2 67
Ralstonia pickettii ATCC 27511 2 ND 19 (6) 68
Salmonella enterica serovar Typhimurium ATCC 14028s 25 ND 100 ATCC
Staphylococcus aureus (VISA) T27857 3 ND ND UWd
Staphylococcus aureus (VISA) M32276 2 ND ND UWd
Staphylococcus aureus (VISA) T57502 3 ND ND UWd
Streptococcus pyogenes MGAS5005 0.6 (0.2) ND 2 69
a MICs for bactobolins A, B, and C were determined with two independent experiments. The range is indicated in parentheses.
b American Type Culture Collection.
c Data previously reported (3).
d Environmental isolate from Brazil, NCBI GenBank database, accession number AJ238360, 1999; human infection (1258b) or environmental (E0274) isolate from the Mahidol-
Oxford Tropical Medicine Research Unit, Bangkok, Thailand (unpublished); human infection isolates from the UW Medical Center Clinical Microbiology Laboratory.
e Imipenem resistant.
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andbecauseincomparisontosensitivemembersoftheProteobac-
teria,forexample,itseemedlesslikelythattherewouldbeaspon-
taneous bactobolin permeability mutation rather than a target
mutation. We spread B. subtilis cells on LB (Luria-Bertani) agar
containing ﬂuid from 30°C-grown B. thailandensis cultures
(about 7.5 l culture ﬂuid per ml LB agar and about 108 cells per
plate,asdescribedinMaterialsandMethods).Coloniesaroseafter
2 days at 37°C at a frequency of about 3  109 cells. We isolated
four mutants by streaking on LB agar containing B. thailandensis
culture ﬂuid for further study. We compared the bactobolin A
MICs for each mutant to that of the parent. The MIC for the
parent was 3 g per ml, and the four mutant MICs were 17, 21,
100, and 100 g per ml (Table 2).
Identiﬁcation of mutations in bactobolin-resistant B. subti-
lismutants.Asaﬁrstapproach,weperformedashotgunsequence
analysis by using an Illumina sequencing platform. We identiﬁed
single mutations in two of the four isolates but none in the two
isolates with the highest levels of resistance. The mutations we
identiﬁed were both rplB (BSU1190) missense mutations (Ta-
ble2)(E236AandE236Q).TherplBproductisthe50Sribosome-
associated protein L2. Because two of the four bactobolin-
resistant mutants had rplB mutations, we reasoned that there
might be rplB mutations in the other two mutants that were not
detected by using the Illumina sequencing platform. Thus, we
PCRampliﬁedandsequencedrplBfromeachofourfourmutants.
In the ﬁrst two, mutations coding for E236A and E236Q were
conﬁrmed, and no other mutations were identiﬁed. In the re-
maining two, we identiﬁed an identical 3-bp insertion (Table 2)
(codingfor235G).Theseinsertionmutationswereoverlookedby
our whole-genome sequencing method, likely due to the strin-
gencyofthealignmentmethodused(12).Theinsertionmutation
resulted in a higher level of resistance to bactobolin A than did
either of the base substitution mutations (Table 2). We were un-
able to sufﬁciently assess resistance to the other six bactobolins
duetotheirweakactivities(2,3).Allfourmutantsshowedasmall
(10%) reduction in growth rate in LB broth relative to that of
theirparent(datanotshown),suggestingthereisacostassociated
with harboring these bactobolin resistance mutations.
TodeterminewhetherexpressionofamutantL2proteinalone
can confer bactobolin resistance, we placed the L2 235G gene be-
hind a lac promoter and moved it into a neutral site (amyE)i n
B.subtilisJH642.WethencomparedtheMICsofthisstraingrown
with or without isopropyl--D-thiogalactopyranoside (IPTG) in-
duction of the lac-promoter-controlled (235G) rplB mutant with
the MIC of a control (B. subtilis JH642 with a wild-type lac-
promoter-controlled rplB gene). For the control, the MIC was
similar to that of the parent grown with or without IPTG. The
strainwiththelac-promoter-controlled235Ggeneshowedasub-
stantially increased MIC when grown in the presence of IPTG
(Table 3). The resistance was intermediate between those of sus-
ceptiblestrainsandthe235Gisolate.Thiswaspresumablybecause
our engineered strain contains two copies of rplB, a wild type and
a mutant gene.
Bactobolin-resistant mutants remain susceptible to other
antibiotics that target ribosomes. Many antibiotics target the ri-
bosome, but we are not aware of any role of L2 in conferring
resistancetoantibioticsthatinterferewithproteinsynthesis.Nev-
ertheless, it may be that the rplB mutations we selected confer
resistance to other antibiotics that target the ribosome. Thus, we
tested the effects of several ribosome-inhibiting antibiotics on
B. subtilis 3610 and on strains carrying the three different rplB
mutations conferring bactobolin resistance we identiﬁed (Ta-
ble 2). The antibiotics tested were kanamycin, which targets the A
site of the 30S subunit, chloramphenicol, clindamycin and lin-
ezolid,whichtargetthepeptidyltransferasecenterofthe50Ssub-
unit, and erythromycin, which targets the peptide exit tunnel of
the 50S subunit (8). The sensitivities of B. subtilis to these antibi-
otics were not altered appreciably in the L2 mutants. If anything,
themutantswereslightlymoresensitivetosomeoftheantibiotics.
These results support the view that the site of bactobolin interac-
tion is speciﬁc for this group of ribosome inhibitors.
DISCUSSION
OurresultsshowthatamongthebactobolinsproducedbyB.thai-
landensis, bactobolin A and bactobolin C are potent broad-
spectrum antibiotics (Table 1). By isolating and studying sponta-
neous B. subtilis bactobolin-resistant mutants, we provide
evidence that resistance to bactobolins occurs through the ribo-
some 50S subunit L2 protein, the product of rplB. The L2 protein
isquiteconserved(Fig.4),andthereisinfactahomologinthe50S
subunitoftheeukaryoticribosomecalledL8e.Theresistancemu-
tations we found map to a particularly well-conserved region of
the protein. The conservation of L2 (L8e) may account for the
broad-spectrumactivityexhibitedbybactobolinAandbactobolin
C. We imagine that the conserved eukaryotic L8e protein is in-
TABLE 2 Susceptibilities of B. subtilis bactobolin-resistant mutants to
bactobolin A, bactobolin B, and other antibiotics
Mutationb
MIC (g per ml)a
Bact A Bact B Cm Clin Ery Kan Lin
None 3 (1) 50 7 (5) 4 (2) 0.7 (0.6) 2 (1) 2 (3)
E236A 17 (6) 200 5 (2) 3 (3) 0.3 (0.1) 2 (1) 1 (1)
235Gc 100 200 3 (1) 2 (1) 0.3 (0.3) 2 (1) 1 (0.2)
E236Q 21 (6) 200 5 (2) 4 (3) 0.3 (0.1) 2 (1) 1 (1)
a MICs were determined with three independent experiments, and the range is
indicated in parentheses. Antibiotics are bactobolin A (Bact A), bactobolin B (Bact B),
chloramphenicol (Cm), clindamycin (Clin), erythromycin (Ery), kanamycin (Kan), and
linezolid (Lin).
b Strains shown are wild-type B. subtilis 3610 and the bactobolin-resistant mutants of
3610 with the indicated amino acid changes in L2 (encoded by rplB), corresponding
with the following base changes (in order of appearance in the table): A708C, 706GGT,
and G706C.
c Two 235G variants were initially identiﬁed, and results with the two were identical.
TABLE 3 Activities of bactobolin A against engineered B. subtilis
strains
Strainb
MIC (g per ml)a
IPTG IPTGc
B. subtilis JH624 3 2 (1)
B. subtilis JH624 spec 3 4 (2)
B. subtilis JH624 L2 spec 66
B. subtilis JH624 L2235G spec 4 (1) 17 (6)
a MICs are the means for three independent experiments, with the ranges indicated in
parentheses.
b We used the naturally competent B. subtilis JH642 and JH642 derivatives with a
chromosomal copy of a spectinomycin-resistant gene (spec), with spec plus an IPTG-
inducible wild-type rplB gene (L2 spec), or with spec plus a mutant rplB gene encoding
L2235G (L2235G spec).
c IPTG was ata1m Mconcentration.
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® mbio.asm.org November/December 2012 Volume 3 Issue 6 e00499-12FIG 4 Multiple alignments of L2 proteins. Conserved amino acids are in black. The bar above the residues corresponding to B. subtilis L2 61 to 202 represents
thecentralRNA-bindingdomain(21).TheopencircleaboveB.subtilisL2H230(previouslyreportedasH229)indicatesaresidueknowntobeessentialforPTC
(peptidyl-transferasecenter)function(23,27).TheﬁlledcirclesaboveB.subtilisG235andE236indicatetheresiduescorrespondingwiththemutationsidentiﬁed
in this study (235G, E236A, and E236Q) (Table 2). The L2 sequences of B. pseudomallei and B. thailandensis were identical. The aligned sequences are from
B.subtilis3610,E.coliK-12,B.pseudomalleiK96243,H.inﬂuenzae6P18H1,P.mirabilisHI4320,S.aureusCOL(methicillin-resistantS.aureus[MRSA]),andMus
musculus mitochondria.
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that potencies of bactobolins A to C in ﬁbroblasts correlate with
potencyinbacteriaisconsistentwiththeideathatL8eplaysarole
in the eukaryotic activity of bactobolins.
Based on sequence conservation and its importance in the ri-
bosome,L2isthoughttobeoneofthemostevolutionarilyancient
ribosome-associated proteins (13). L2 is required for the associa-
tion between the 50S and 30S ribosomal subunits and for full
activity of the PTC (14). In fact, L2 is one of only a few proteins
that are necessary for elongation of peptides (15–18). L2 is com-
prised of a central RNA-binding domain (RBD) (residues 61 to
202) (Fig. 4), which localizes to the outside of the ribosome, and
ﬂexible N and C termini that extend into the ribosome and are
proximal to the PTC (19–22). The central RBD interacts with
domain IV of the 23S rRNA and mediates contacts between the
50S and 30S subunits (18, 23–26). The C terminus of L2, in par-
ticular residue H230 (reported previously as H229), is critical for
peptidyl transferase activity (27). This region is thought to stabi-
lize the PTC-containing domain V of the 23S rRNA, allowing
movement of tRNAs through the ribosome (23, 27). The
bactobolin-resistant mutations mapped just in this region (Ta-
ble 2; Fig. 4). The association of this L2 region with the PTC sug-
gests that the bactobolins may inhibit peptidyl transfer speciﬁ-
cally.TheactivitiesofotherantibioticsthattargetthePTCarenot
altered by the L2 mutations (Table 2). In fact, relatively few ribo-
somal proteins have known roles in antibiotic resistance, and
these include L4, L6, L11, L16, L22, S5, S12, and S17 (28–37).
Althoughinafewcasestheantibioticsmayinteractdirectlywitha
ribosomalprotein(38,39),itiscommonthatthemutatedprotein
alters an rRNA target (40–43). For example, mutations in the S12
ribosomal protein confer resistance to streptomycin by causing
structural changes in its rRNA target (40). Most antibiotics target
rRNAs (44). Proteins comprise much less total ribosome surface
areathanrRNAs,andtheyarenotdirectlyinvolvedinthecatalytic
functions. In the case of bactobolin, direct interaction could be
with L2 itself or an rRNA affected by L2. Our results support the
viewthattheinteractionsiteisnovelbecauseresistancemutations
map to L2 and because the mutations do not confer resistance to
other classes of antibiotics that target the ribosome.
Although bactobolin A and bactobolin C are potent antibiot-
ics,theyarealsoequallytoxictomouseﬁbroblastcells.Thismam-
malian toxicity excludes development of these molecules as anti-
bacterial therapeutics. Nevertheless, because of our identiﬁcation
of a speciﬁc ribosomal protein as a target of bactobolins coupled
with our developing understanding of bactobolin genetics and
chemistry, these molecules or derivatives of these molecules have
potential uses in biology and in applications. Bactobolins may be
ofuseineffortstobetterunderstandribosomefunction.Although
it may not be possible to develop bactobolin derivatives that spe-
ciﬁcally target bacterial ribosomes, the bactobolins may also ﬁnd
utility if they can be targeted to speciﬁc cells, for example, tumor
cells, via developing technologies.
MATERIALS AND METHODS
Bacterial strains, culture conditions, and reagents. We used B. thailan-
densis strain E264 (45) and E. coli DH10B for genetic manipulations. Our
B. thailandensis btaK-lacZ chromosomal insertion mutant (btaK126::
ISlacZ/hah-TC) was from a sequence-deﬁned transposon mutant library
(L.GallagherandC.Manoil,unpublished).Thismutanthasatransposon
insertion in the coding sequence of btaK after bp 2237 relative to the
predicted btaK translational start site. We obtained bactobolin-resistant
mutants of B. subtilis 3610 (46) as described. We used the easily trans-
formed B. subtilis JH642 (47) to create rplB diploids. Other bacteria are
listed in Table 1 or described in the text.
Bacteria were grown in tryptic soy broth (TSB), cation-adjusted
Mueller-Hinton broth (MHB), or morpholinepropanesulfonic acid
(MOPS)-bufferedLBbrothor,foroneexperiment,starchagar(33gtryp-
tose blood agar base and 10 g Argo pure corn starch per liter). When
appropriate, the following antibiotics were used (per ml): 100 g trim-
ethoprim and spectinomycin at 50 g( E. coli)o r1 0 0g( B. subtilis). We
addedisopropyl--D-thiogalactopyranoside(IPTG)(1mM)asappropri-
ate. Bactobolins were isolated from B. thailandensis culture ﬂuid as de-
scribed elsewhere (2, 3).
We measured -galactosidase activity with a Tropix Galacto-Light
Plus chemiluminescence kit according to the manufacturer’s protocol
(Applied Biosystems, Foster City, CA). Genomic DNA, PCR and DNA
fragments, and plasmid DNA were puriﬁed using the DNeasy blood and
tissue kit, PCR or plasmid puriﬁcation kits, or gel extraction kit (Qiagen)
according to the manufacturer’s protocol.
Genetic manipulations. We used standard procedures for DNA ma-
nipulations (48). To assess btaK-lacZ activity in a btaR2 mutant back-
ground, an unmarked, in-frame btaR2 deletion was introduced into the
btaK-lacZ reporter strain by using the deletion construct pJRC115 btaR2
and methods described previously (49). For ectopic expression of L2 and
L2235G in B. subtilis, the genes were placed under control of the IPTG-
inducible promoter on pDR111 (50), and the resulting plasmids were
integrated into the nonessential B. subtilis amyE locus. To clone pDR111
expressing each L2 allele, the genes were ampliﬁed from genomic DNA
isolated from B. subtilis 3610 or the 235G variant, respectively, by using
primers that incorporated an upstream ribosome binding site, AAG
GAGG(51),andrestrictionsites(SphIandNheI)intotheproduct.These
ampliconswerecutwithSphIandNheIandligatedtoSphI-NheI-digested
pDR111. In both cases, rplB was downstream of the pDR111-encoded
Phyperspank IPTG-inducible promoter (50). The resulting constructs were
usedtotransformthenaturallycompetentB.subtilisJH624byestablished
methods (52). Transformants were selected on spectinomycin LB agar,
and disruption of amyE was veriﬁed by lack of hydrolysis on starch agar.
MIC and cytotoxicity assays. The antimicrobial activities of puriﬁed
bactobolins or bactobolin-containing B. thailandensis supernatant were
assessed by using a MIC assay according to the 2003 guidelines of the
Clinical and Laboratory Standards Institute (CLSI) and as described else-
where (3). Fibroblasts were maintained in Dulbecco modiﬁed Eagle me-
dium(DMEM)supplementedwith10%fetalbovineserum(FBS)and10
M minimal essential medium (MEM) with nonessential amino acids
and incubated at 37°C with 5% CO2. Brieﬂy, microtiter dish wells were
seeded with 104 cells in 100 l medium and grown to 50% conﬂuence
(24h).Cellswerethentreatedwithfreshbactobolin-containingmedium.
After 48 h, we determined cell viability with alamarBlue according to the
manufacturer’s instructions (Invitrogen). We determined the inhibitory
dose causing 50% loss of viability (ID50).
Screen for bactobolin-resistant mutants. We used B. thailandensis
culture ﬂuid as a source of bactobolin to isolate bactobolin-resistant
B. subtilis. B. thailandensis was grown to stationary phase (optical density
at 600 nm [OD600] of 8 to 10) in LB broth, and the culture ﬂuid was
clariﬁed by microcentrifugation and ﬁltered through a 0.22-m-pore
membrane.Filteredcultureﬂuidwasstoredat4°Cforupto1monthprior
touse.LBagarplatesweresupplementedwiththeminimalconcentration
of culture ﬂuid required to inhibit growth of a lawn of stationary-phase
B.subtilisafter2days.Thisvariedwitheachbatchofcultureﬂuidbutwas
approximately 7.5 l culture ﬂuid per ml medium. Culture ﬂuid-
supplemented plates were spread with approximately 1  108 stationary-
phase B. subtilis cells. Colonies that grew after 2 days were veriﬁed by
streaking on fresh ﬂuid-supplemented plates.
Illumina sequencing and analysis. Whole-genome resequencing of
our wild-type strain, 3610, and its bactobolin-resistant B. subtilis deriva-
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fragment library was constructed using a custom paired-end protocol.
Brieﬂy,genomicDNA(gDNA)sampleswereshearedbyusingaBioruptor
UCD-200 sonication device (Diagenode Inc. Denville, NJ) and end re-
paired a using an End-It DNA end repair kit (Epicentre). Repaired frag-
mentsweresubjectedtoAtailingusingTaqDNApolymerase(RocheInc.,
Chicago, IL). Custom “Y” adaptors (sequences available upon request)
wereaddedbyusingT4DNAligase(NewEnglandBiolabs,Beverly,MA).
Libraries were size selected by using automated electrophoresis on a Pip-
pen Prep system (Sage Science, Beverly, MA) and assessed for size range
and concentration using a Qubit ﬂuorometer (Invitrogen Inc., Carlsbad,
CA) and a Bioanalyzer system (Agilent Inc., San Diego, CA). Sequencing
was done on an Illumina GAIIx genome analyzer (Illumina, San Diego,
CA) (paired-end 76-bp reads).
TheBurrows-WheelerAlignmentsoftwaretoolwasusedtoalignreads
from sequencing (54). The sequence alignment of each variant was com-
pared with sequence of a close relative of the parent strain, B. subtilis 168
(GenBank accession number CM000487), by using the SAMtools
mpileup method (SourceForge). This yielded a list of single-nucleotide
polymorphisms (SNPs). We used a custom script to identify each SNP as
nonsynonymousorsynonymousandasgenicorintergenic.Wenarrowed
the SNP list to changes that were present in a bactobolin-resistant variant
butnotintheresequenced3610parent.RemainingSNPSwereveriﬁedby
using the genome viewer IgV, version 1.5 (55). Mutations identiﬁed by
this method were veriﬁed by sequencing PCR-ampliﬁed products.
L2 sequence alignments. Amino acid sequences of selected L2 pro-
teins were obtained from the Integrated Microbial Genome Database
(http://img.jgi.doe.gov/cgi-bin/w/main.cgi) and aligned using the soft-
ware tool Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/)
with default settings.
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